RICH.BA Laboratorios Richmond SACIF
- Market cap
- ARS 105B
- P/E
- 6.1x
- P/B
- 0.76x
- ROE
- 21.2%
- Dividend yield
- 2.51%
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RICH.BA undervalued?
Graham numberRICH.BA trades 54.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Laboratorios Richmond SACIF fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (21.2%), above 20%.
ROA 0/1
Return on assets (5.6%) is below the industry median (5.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-90.2%) is not above the 5-year average (44.7% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-90.2%) is below the industry median (-3.6%).
Revenue Growth 2/2
Revenue grew 90.0% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (147.7%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.5x against interest expense, below 5x.
PE vs Market 0/1
PE (7.4x) is above the market median (6.7x).
PE vs Industry 0/1
PE (7.4x) is above the industry median (5.8x).
PBV 0/1
Price to book (0.9x) is above the industry median (0.8x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 6.8, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.17, growth is cheap.
Dividend Yield 1/2
Dividend yield (2.5%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 85.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Laboratorios Richmond SACIF stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East. It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, ant…
Full company profileLaboratorios Richmond SACIF financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Laboratorios Richmond SACIF annual financial statements (ARS; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 856M | 982M | 1.82B | 3.90B | 6.18B | 16.6B | 18.5B | 85.0B | 121B | 127B | 123B |
| Gross Profit | 467M | 519M | 805M | 1.89B | 3.01B | 4.93B | 8.73B | 44.8B | 65.8B | 78.2B | 73.5B |
| Operating Income | 239M | 170M | 129M | 797M | 1.51B | 2.32B | 3.04B | 11.5B | 21.4B | 33.3B | 3.69B |
| EBITDA | - | 129M | -88.6M | 489M | 1.21B | 2.51B | 2.96B | -13.7B | 56.2B | 33.6B | 67.5B |
| Net Income | 94.8M | 40.8M | -216M | 116M | 486M | 591M | 163M | -23.6B | 31.4B | 3.09B | 25.0B |
| EPS | - | 0.50 | -2.67 | 1.44 | 6.02 | 7.32 | 2.02 | -293 | 388 | 38 | 310 |
| Balance Sheet | |||||||||||
| Total Assets | 861M | 1.55B | 2.71B | 5.13B | 8.13B | 25.7B | 40.7B | 337B | 342B | 420B | 447B |
| Total Liabilities | 672M | 865M | 1.59B | 3.03B | 4.75B | 20.3B | 30.5B | 287B | 256B | 327B | 328B |
| Shareholders' Equity | 150M | 688M | 1.05B | 2.05B | 3.38B | 5.29B | 10.1B | 49.1B | 84.6B | 91.5B | 118B |
| Cash & Short-term Investments | 16.2M | 538M | 501M | 217M | 494M | 4.67B | 1.26B | 1.39B | 9.23B | 10.8B | 2.93B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.67M | 11.2M | -182M | 121M | -181M | 7.27B | -4.29B | -4.54B | 7.40B | 1.87B | 29.7B |
| Capital Expenditure | 10.8M | 76.7M | 244M | 379M | 561M | 10.3B | 6.69B | 27.3B | 11.6B | 54.3B | 17.0B |
| Free Cash Flow | - | -42.9M | -372M | -361M | -717M | -2.19B | -11.8B | -31.8B | -4.19B | -52.5B | 12.7B |
| Ratios | |||||||||||
| ROE | 63.1% | 5.9% | -20.5% | 5.7% | 14.4% | 11.2% | 1.6% | -48.1% | 37.1% | 3.4% | 21.2% |
| ROA | 11.0% | 2.6% | -8.0% | 2.3% | 6.0% | 2.3% | 0.4% | -7.0% | 9.2% | 0.7% | 5.6% |
| Net Profit Margin | 11.1% | 4.1% | -11.9% | 3.0% | 7.9% | 3.6% | 0.9% | -27.8% | 26.0% | 2.4% | 20.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Laboratorios Richmond SACIF dividends
- Dividend yield
- 2.51%
- Forward dividend
- 32.61 ARS
- Payout ratio
- 85.2%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | ARS 2.63B | 33 | 85.2% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | ARS 509M | 6.30 | 311.3% |
| 2021 | ARS 135M | 1.67 | 22.8% |
| 2020 | ARS 135M | 1.67 | 27.8% |
| 2019 | ARS 135M | 1.67 | 115.9% |
| 2018 | ARS 21.1M | 0.26 | - |
| 2017 | ARS 40.1M | 0.50 | 98.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Laboratorios Richmond SACIF
- Insiders 0.00%
- Institutions 9.01%
- Public & others 90.99%
- Shares outstanding 66.6M
- Free float 14.2M
Laboratorios Richmond SACIF company profile
- Company name
- Laboratorios Richmond SACIF
- Ticker
- RICH.BA
- ISIN
- ARLRIC300027
- Exchange
- Buenos Aires Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Bouchard 680, Buenos Aires, Argentina
- Phone
- 54 11 5555 1600
- Website
- richmondlab.com
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East. It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, antipsychotics, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company was incorporated in 1959 and is headquartered in Buenos Aires, Argentina.
Laboratorios Richmond SACIF management
4- Juan Manuel ArtolaCEO & Director
- Ruben Jorge AlvarezChief Financial Officer
- R.A. Patricio CarballesVP of Legal Affairs & Director
- Norberto Pablo Garcia SantallinExecutive VP & Director